Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04817007
Title A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | AUS

No variant requirements are available.